Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Overview of attention for article published in Journal of Hematology & Oncology, March 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

policy: 2 policy sources
twitter: 3 X users

guideline: 3 clinical guideline sources

Readers on

mendeley: 127 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 80,257 followers.

$SGEN #ASH14 @AlpineBV_Miller @kokurasluck @dsobek Think 30% CR with Adcetris retreatment is for CD30+ pts only? http://t.co/IAUeAkZZNt

$SGEN #ASH14 @AlpineBV_Miller @kokurasluck @dsobek Think 30% CR with Adcetris retreatment is for CD30+ pts only? http://t.co/IAUeAkZZNt

$SGEN #ASH14 @AlpineBV_Miller @kokurasluck @dsobek Think 30% CR with Adcetris retreatment is for CD30+ pts only? http://t.co/IAUeAkZZNt

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.

Login to access the Sentiment Analysis related to this output.